Zhi Tong Cai Jing·2025-09-05 15:26Core Viewpoint - The innovative drug sector is expected to continue its strong performance, with significant clinical data releases from Chinese innovative drugs at major conferences in the latter half of the year, potentially leading to a market surge similar to the one seen in May at the American Oncology Conference [1] Group 1: Market Performance - BeiGene (ONC.US) shares rose by 6%, reaching $338.19 [1] - The innovative drug sector is anticipated to maintain high revenue growth and a trend of reduced losses year-on-year, with some leading companies approaching breakeven [1] Group 2: Upcoming Events - Major conferences such as the World Lung Cancer Conference, European Oncology Congress, and American Hematology Annual Meeting are set to showcase key clinical data for Chinese innovative drugs [1] Group 3: International Collaboration - There is an increase in licensing negotiations between Chinese companies and multinational corporations (MNCs), with several potential blockbuster drugs entering advanced negotiation stages [1] - The next two to three years will see a significant number of patent expirations for major drugs from global pharmaceutical companies, creating opportunities for Chinese innovative drugs to fill the gaps [1] Group 4: Industry Outlook - The innovative drug sector is experiencing a rise in international recognition for its innovative capabilities, with active licensing transactions reaching new highs in both quantity and value [1] - Increased collaboration between multinational pharmaceutical companies and Chinese firms is expected to enhance market valuation expectations for the innovative drug sector [1]